LogicBio Therapeutics, Inc. Revenue
LogicBio Therapeutics, Inc. reported Revenue of $2.72 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2022-11-14
- LogicBio Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-09-30 was $2.72M, a 28.16% increase year-over-year.
- LogicBio Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-06-30 was $3.20M, a 298.88% increase year-over-year.
- LogicBio Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-03-31 was $2.82M, a 510.85% increase year-over-year.
- LogicBio Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2021-12-31 was $2.03M, a 273.99% increase year-over-year.
- LogicBio Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $5.41M, a 56.63% increase from fiscal 2020.
- LogicBio Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $3.45M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2022-09-30 | $2.72M 10-Q · filed 2022-11-14 | $5.92M derived: sum of 2 quarters · filed 2022-11-14 | $8.73M 10-Q · filed 2022-11-14 | $10.76M derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | $3.20M 10-Q · filed 2022-08-15 | $6.01M 10-Q · filed 2022-08-15 | $8.04M derived: sum of 3 quarters · filed 2022-08-15 | $10.16M derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-03-31 | $2.82M 10-Q · filed 2022-05-16 | $4.84M derived: sum of 2 quarters · filed 2022-05-16 | $6.96M derived: sum of 3 quarters · filed 2022-11-14 | $7.76M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $4.15M derived: sum of 2 quarters · filed 2022-11-14 | $4.95M derived: sum of 3 quarters · filed 2022-11-14 | $5.41M 10-K · filed 2022-03-04 |
| 2021-09-30 | $2.12M 10-Q · filed 2022-11-14 | $2.92M derived: sum of 2 quarters · filed 2022-11-14 | $3.38M 10-Q · filed 2022-11-14 | $3.92M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $802.00K 10-Q · filed 2022-08-15 | $1.26M 10-Q · filed 2022-08-15 | $1.80M derived: sum of 3 quarters · filed 2022-08-15 | $2.73M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $461.00K 10-Q · filed 2022-05-16 | $1.00M derived: sum of 2 quarters · filed 2022-05-16 | $1.93M derived: sum of 3 quarters · filed 2022-05-16 | $2.89M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $542.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $1.47M derived: sum of 2 quarters · filed 2022-03-04 | $2.43M derived: sum of 3 quarters · filed 2022-03-04 | $3.45M 10-K · filed 2022-03-04 |
| 2020-09-30 | $926.00K 10-Q · filed 2021-11-15 | $1.89M derived: sum of 2 quarters · filed 2021-11-15 | $2.91M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $965.00K 10-Q · filed 2021-08-09 | $1.99M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $1.02M 10-Q · filed 2021-05-10 |